Benzinga  Mar 24  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel's leading international marketing group for innovative pharmaceuticals, today announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig®...
Market Intelligence Center  Mar 6  Comment 
Ariad Pharmaceuticals (ARIA) was selected by MarketIntelligenceCenter.com’s trade-picking algorithms today after trading between $8.25 and $8.65 on Thursday before closing at $8.25. A diagonal spread using a long position in the Jan. '16 $5.00...
Motley Fool  Mar 5  Comment 
Ariad Pharmaceuticals' shares rocket to their highest levels since last Spring following a double-dose of positive news for shareholders. Find out whether this momentum can continue.
Motley Fool  Feb 20  Comment 
Ariad Pharmaceuticals shares are jumping following its earnings yesterday and news of an upcoming proxy fight.
Benzinga  Feb 20  Comment 
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) share were trading higher by $0.83 (11 percent) at $8.10 in Friday's session. It appears to be a reaction to...
TheStreet.com  Feb 20  Comment 
NEW YORK (TheStreet) -- Activist hedge fund Sarissa Capital is starting a proxy fight to force the ouster of Ariad Pharmaceuticals founder and CEO Harvey Berger. Sarissa, led by former Carl Icahn lieutenant Alex Denner, is Ariad's largest...
Forbes  Feb 17  Comment 
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money.  So let's look at two noteworthy recent insider buys.


Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki